Professional Documents
Culture Documents
Apa 11 Antipsychotic Schizophrenia
Apa 11 Antipsychotic Schizophrenia
Apa 11 Antipsychotic Schizophrenia
Janssen Pharmaceutica Products LP, Titusville, NJ; 2Consumer Health Sciences, Princeton, NJ
Methods: Schizophrenia patients (N=390) identified through the National Alliance for the Mentally
Ill (NAMI) and community mental health centers completed self-administered questionnaires in
June 2000. Those reporting any paid employment, volunteer work, or school were considered
productive. To determine the association of antipsychotic medications with productive activity, a
logistic regression was used, controlling for disease severity, demographics, and other prescription
medications. The Psychological General Well-Being Scale (PGWB) was used as a surrogate
measure for disease severity.
Results: An average of 53% of respondents participated in at least one productive activity a week.
Thirty-three percent engaged in paid employment, 26% engaged in volunteer work, and 9% were in
school. Respondents with less severe disease were more likely to be productive (P=0.001).
Although risperidone users had more severe disease than did patients receiving conventional
antipsychotics (PGWB scores 60.7 vs. 66.4), this did not negatively affect productivity. Fifty-eight
percent of risperidone users were productive compared with 49% of patients receiving conventional
antipsychotics. Logistic regression found that risperidone was the only antipsychotic in either group
(conventional or atypical) that was significantly associated with productive activities (OR=1.85,
P=0.047).
Conclusion: Risperidone use had a positive impact on the productivity of community patients with
schizophrenia.
The PGWB scale consists of 22 questions designed to measure individuals subjective feelings
of well-being or distress.
Scores range from 0 to 110
Higher scores indicate greater well-being
Statistical Analyses
To control for the effects of other variables that could potentially explain or confound patients
productivity, a logistic regression model was used.
OBJECTIVES
To determine the impact of antipsychotic use on the productivity and functioning of individuals
with schizophrenia in the community.
Data Collection
METHODS
Patient Sample
Patients were identified through national chapters of the National Mental Health Association
(NMHA), the National Alliance for the Mentally Ill (NAMI), and community mental health centers.
70
60
50
40
30
20
10
0
58
60
60
Clozapine
(N=81)
Medication Use
RESULTS
Demographic characteristics by use of antipsychotic medication#
Male/female (%)
55/45
45.6 (9.6)*
White/nonwhite (%)
55/45
46/54
57/43
80/20
82/18
89/11
80/20
55/45
42.1 (7.6)
89/11*
In this population, less elderly patients (65 years) used atypical antipsychotics.
More whites than nonwhites used antipsychotics.
Percent
n=
31
119
23
9
29
22
38
15
31
25
6
91
35
114
85
147
60
119
97
23
Traditional antipsychotics
Atypical antipsychotics
Risperidone
Quetiapine
Olanzapine
Clozapine
Antidepressants
Anxiolytics
Anticholinergics
Mood stabilizers
Sedatives
Traditional
antipsychotics Risperidone Quetiapine Olanzapine Clozapine
n=119
n=91
n=35
n=114
n=85
Odds Ratio
95% CI
0.0001
0.2325
0.0094
0.0057
0.6925
0.0473
0.6749
0.3960
0.2599
0.3158
0.6816
0.0231
0.0511
0.1708
1.0233
0.7473
2.3063
0.9671
1.1238
1.8504
1.1901
1.2838
1.4274
1.2947
1.1522
0.5247
0.5780
0.4434
1.0115 1.0352
0.4632 1.2055
1.2276 4.3331
0.9445 0.9903
0.6303 2.0037
1.0073 3.3992
0.5277 2.6835
0.7210 2.2860
0.7686 2.6511
0.7816 2.1447
0.5855 2.2673
0.3008 0.9154
0.3332 1.0026
0.1385 1.4198
53
49
Control variables included schizophrenia severity (as measured by the PGWB), gender, age, and
race, and use of other prescription medications including: antidepressants, anxiolytics,
anticholinergics, mania drugs, and sedatives.
INTRODUCTION
The improvement of quality of life and productivity is a major challenge in the treatment of
schizophrenic patients. Ideal drug treatment is important in the management of patients disease
and social functioning.
Severity was defined using the Psychological General Well-Being Scale (PGWB).
Percent with
Productive Activities
Objective: To evaluate the association of antipsychotic medication with the productivity of people
with schizophrenia.
Measures
Severity (PGWB)
Gender (female)
Race (white)
Age
Traditional antipsychotic
Risperidone
Quetiapine
Olanzapine
Clozapine
Antidepressant
Anxiolytic
Anticholinergic
Mood stabilizer
Sedative
Younger patients were more likely to be productive regardless of type of medication use
(P < 0.01).
Patients with less severe disease were more likely to be productive regardless of type of
medication use (P < 0.01).
Caucasian patients were more likely to be productive regardless of type of medication use
(P < 0.01).
Patients could have used more than one type of psychotropic agent.
Traditional
antipsychotics
Risperidone
Severity of Schizophrenia
Quetiapine
Productive Activity
Those who reported any hours of paid employment, volunteer or unpaid work, or school or
college were classified as engaging in productive activity.
Fifty-three percent of respondents participated in at least one productive activity in an average
week for a mean of 7.16 hours per week.
33%
26%
9%
ABSTRACT
67.0
66.0
65.0
64.0
63.0
62.0
61.0
60.0
59.0
58.0
57.0
Olanzapine
66.4
65.4
Clozapine
62.6
The lines represent 95% confidence intervals for each groups odds ratio.
60.7
Logistic regression revealed that only patients using risperidone were 1.85 times more likely to
engage in a productive activity than those not using risperidone (P < 0.05).
Traditional Risperidone
Antipsychotics
(N=89)
(N=114)
Quetiapine
(N=35)
Olanzapine
(N=109)
Clozapine
(N=81)
Patients given risperidone appeared to have more severe illness than did other antipsychotic
users.
CONCLUSIONS
Although risperidone users were more severely ill compared with conventional antipsychotic
users (PGWB scores 60.7 vs. 66.4), this did not negatively affect productivity.
Risperidone use had a positive impact on the productivity of people with schizophrenia in the
community.